Medisan(SZ:002900) Shang Hai Zheng Quan Bao·2025-09-22 19:29Group 1: Board Meeting Overview - The fourth meeting of the Board of Directors of Harbin Sanlian Pharmaceutical Co., Ltd. was held on September 22, 2025, via electronic communication [2][3] - All 9 directors were present at the meeting, and it was chaired by Chairman Qin Jianfei [4][5] - The meeting complied with relevant laws and regulations, including the Company Law of the People's Republic of China [5] Group 2: Resolutions Passed - The Board approved the proposal to use idle self-owned funds for entrusted financial management [6][8] - The voting results showed 9 votes in favor, with no votes against or abstentions [7] Group 3: Supervisory Meeting Overview - The fourth meeting of the Supervisory Board was also held on September 22, 2025, in person [13] - All 3 supervisors attended the meeting, which was chaired by Chairman Zhai Yuping [13][14] - The meeting adhered to legal and regulatory requirements [13] Group 4: Supervisory Resolutions - The Supervisory Board approved the same proposal regarding the use of idle self-owned funds for entrusted financial management, stating it would not affect the company's daily operations [14][15] Group 5: Financial Management Proposal - The company plans to use up to RMB 300 million of idle self-owned funds for entrusted financial management within one year [18][19] - The investment aims to enhance the efficiency of fund usage and ensure the preservation and appreciation of funds [19] - The funds will be invested in high-credit, liquid financial instruments through qualified financial institutions [19] Group 6: Investment Risk Management - The company will select safe and liquid financial products and monitor the investment closely to mitigate risks [22][24] - Internal audits will be conducted to ensure compliance and proper management of the invested funds [24] Group 7: Impact on the Company - The use of idle funds for financial management is expected to improve fund efficiency and generate investment returns without affecting the company's normal operations [24][25]